← All trials
NCT05632133
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- Dec 10, 2022
- Completion date
- Dec 30, 2022
- First posted
- Nov 30, 2022
- Last posted
- Nov 30, 2022
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kafrelsheikh UniversityLead sponsor
- Kafrelsheikh UniversityOverall official - principal investigator
- Kafrelsheikh UniversityReponsible party - principal investigator
- Kafrelsheikh UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.